#	Pagina
attuale pagina	/open-h2020/projects/209443/index.html

Opendata, web and dolomites

VSV-EBOVAC SIGNED

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

VSV-EBOVAC project word cloud

Explore the words cloud of the VSV-EBOVAC project. It provides you a very rough idea of what is the project "VSV-EBOVAC" about.

trials determinants aditec 100 gabon africa zaire man world perform ebola manufactured volunteers powerful organization genetics critical lasting collaborative virus candidate innate supporting immune protective vesicular zebov stomatitis extend trancriptomics 12 emphasis dose adaptive inducing switzerland canada months cutting populations efficacy vsv antibody mid immunisation vaccination capacity first generation vaccines edge candidates 200 scientists single immunization health doses vectored newlink clinical public primary imi2 fp7 characterization leaders asset humans signatures immunology initiated 2014 african metabolomics kenya technologies persistent ebovac sites constructed vaccine parallel elicited safety human primates manufacturer samples accelerate infections harvested acquire november

Project "VSV-EBOVAC" data sheet

The following table provides information about the project.

Coordinator	SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.vsv-ebovac.eu
Total cost	4˙786˙010 €
EC max contribution	3˙887˙260 € (81%)
Programme	1. H2020-EU.3.1.7.13. (Other)
Code Call	H2020-JTI-IMI2-2014-02-single-stage
Funding Scheme	IMI2-RIA
Starting year	2015
Duration (year-month-day)	from 2015-03-01 to 2019-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SCLAVO VACCINES ASSOCIATION SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	coordinator	841˙250.00
2	GOETEBORGS UNIVERSITET GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 website: www.gu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOETEBORG)	participant	700˙000.00
3	EMORY UNIVERSITY NON PROFIT CORP EMORY UNIVERSITY NON PROFIT CORP Organization address address: Clifton Road, NE, 4th Floor 1599 city: Atlanta postcode: 30322 website: www.osp.emory.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (Atlanta)	participant	600˙888.00
4	UNIVERSITA DEGLI STUDI DI SIENA UNIVERSITA DEGLI STUDI DI SIENA Organization address address: VIA BANCHI DI SOTTO 55 city: SIENA postcode: 53100 website: www.unisi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	562˙500.00
5	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	522˙552.00
6	MICROBIOTEC SRL MICROBIOTEC SRL Organization address address: VIA DELLE VIGNE 12 city: MONTERIGGIONI postcode: 53035 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MONTERIGGIONI)	participant	212˙500.00
7	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	131˙820.00
8	Department of Health Department of Health Organization address address: Quarry House, Quarry Hill city: Leeds postcode: LS2 7UE website: www.dh.gov.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (Leeds)	participant	125˙000.00
9	Centre de Recherches Medicales de Lambaréné Centre de Recherches Medicales de Lambaréné Organization address address: NA city: Lambaréné postcode: 118 website: www.cermel.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	GA (Lambaréné)	participant	118˙875.00
10	BIOPROTECTION SYSTEMS CORPORATION BIOPROTECTION SYSTEMS CORPORATION Organization address address: 2503 SOUTH LOOP DRIVE SUITE 5100 city: AMES postcode: 50010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (AMES)	participant	62˙500.00
11	EBERHARD KARLS UNIVERSITAET TUEBINGEN EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 website: www.uni-tuebingen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	9˙375.00
12	EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT Organization address address: BUNDESHAUS OST city: BERN postcode: CH-3003 website: http://www.vbs.admin.ch/internet/vbs/en/home/departement.html/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BERN)	participant	0.00
13	UNIVERSITE DE GENEVE UNIVERSITE DE GENEVE Organization address address: RUE DU GENERAL DUFOUR 24 city: GENEVE postcode: 1211 website: www.unige.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	participant	0.00

Map

Project objective

The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)â€ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations.

We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.

Deliverables

List of deliverables.
Predictive correlates of protective immunity and safety determined.	Documents, reports	2019-10-01 09:22:26
Establishment of the External Advisory Board	Documents, reports	2019-06-19 17:57:00
Distribution of early samples (day 0-14) to partners involved in immunogenicity studies	Documents, reports	2019-06-19 17:57:00
Distribution of intermediate samples (day 28) to partners involved in immunogenicity studies	Documents, reports	2019-06-19 17:57:00
Web site development and maintenance	Websites, patent fillings, videos etc.	2019-06-19 17:57:00
Distribution of late samples (> day 28) to partners involved in immunogenicity studies	Documents, reports	2019-06-19 17:57:00

Take a look to the deliverables list in detail: detailed list of VSV-EBOVAC deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Donata Medaglini, Claire-Anne Siegrist Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine published pages: 88-94, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2017.03.008	Current Opinion in Virology 23	2019-06-19
2018	Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, JosÃ© F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara LemaÃ®tre, StÃ©phane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÃ„HLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, JosÃ© F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8	The Lancet Infectious Diseases 18/7	2019-06-19
2018	Angela Huttner, Claire-Anne Siegrist Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582	Expert Review of Vaccines 17/12	2019-06-19
2017	Angela Huttner, Christophe Combescure, StÃ©phane Grillet, MariÃ«lle C. Haks, Edwin Quinten, Christine Modoux, Selidji Todagbe Agnandji, Jessica Brosnahan, Julie-Anne Dayer, Ali M. Harandi, Laurent Kaiser, Donata Medaglini, Tom Monath, Pascale Roux-Lombard, Peter G. Kremsner, Tom H. M. Ottenhoff, Claire-Anne Siegrist A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa published pages: eaaj1701, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaj1701	Science Translational Medicine 9/385	2019-06-19
2018	Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist Correlates of vaccine-induced protective immunity against Ebola virus disease published pages: 65-72, ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003	Seminars in Immunology 39	2019-06-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VSV-EBOVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.13.)

EBOVAC1 (2014)

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

VSV-EBOVAC (2015)

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

ADAPT-SMART (2015)

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890